Kathryn de Santis
Investor Relations Kontakt bei Sucampo Pharma Americas, Inc.
Profil
Kathryn de Santis is currently the VP-Investor Relations & Corporate Communications at Sucampo Pharma Americas, Inc. She previously held the same position at Sucampo Pharmaceuticals, Inc. and was the Director-Corporate Communications at Human Genome Sciences, Inc. She received an undergraduate degree from Molloy College and an MBA from Pace University.
Aktive Positionen von Kathryn de Santis
| Unternehmen | Position | Beginn |
|---|---|---|
| Sucampo Pharma Americas, Inc. | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Kathryn de Santis
| Unternehmen | Position | Ende |
|---|---|---|
| SUCAMPO PHARMACEUTICALS, INC. | Investor Relations Kontakt | 29.06.2012 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Public Communications Contact | - |
Ausbildung von Kathryn de Santis
| Molloy College | Undergraduate Degree |
| Pace University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
| Sucampo Pharma Americas, Inc. |
